EP1507771A1 - Isothiazolone composition and method for stabilizing isothiazolone - Google Patents

Isothiazolone composition and method for stabilizing isothiazolone

Info

Publication number
EP1507771A1
EP1507771A1 EP03755296A EP03755296A EP1507771A1 EP 1507771 A1 EP1507771 A1 EP 1507771A1 EP 03755296 A EP03755296 A EP 03755296A EP 03755296 A EP03755296 A EP 03755296A EP 1507771 A1 EP1507771 A1 EP 1507771A1
Authority
EP
European Patent Office
Prior art keywords
isothiazolone
group
stabilizing
isothiazolone composition
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03755296A
Other languages
German (de)
French (fr)
Other versions
EP1507771A4 (en
Inventor
Wan-Pyo 104-1003 Hansin apt. HONG
Jin-Man 306-1303 LG Village apt. KIM
Ki-Seung 103-302 Jindalrae apt. CHOI
Jin-Ho 712-105 Mugunghwa apt. KIM
Ki-Man 102-708 Dongsin apt. PARK
Hi-Weon 649-18 Seryu 2-dong JUNG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Chemicals Co Ltd
Original Assignee
SK Chemicals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020020062096A external-priority patent/KR20030093086A/en
Application filed by SK Chemicals Co Ltd filed Critical SK Chemicals Co Ltd
Publication of EP1507771A1 publication Critical patent/EP1507771A1/en
Publication of EP1507771A4 publication Critical patent/EP1507771A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom

Definitions

  • US Patent No. 3,870,785 has suggested a method of adding a metal nitrate salt, a nitrite salt, etc. to the composition as a stabilizer.
  • US Patent No. 4,165,318 has suggested a method of adding formaldehyde or a formaldehyde-eluting material to an isothiazolone composition as a stabilizer.
  • US Patent No. 4,824,957 has suggested a method of adding an organic hydroxylic solvent to an isothiazolone composition as a stabilizer.
  • a dispersion or an emulsion such as paint acrylate or latex, etc.
  • a sterilizer comprising salts of divalent ions which cause coagulation.
  • sterilization active ingredients may be incorporated into the coagulation, thus the sterilization active ingredient may be reduced or removed if a product to be stored is filtered.
  • Fig. 1 is a photograph showing salt shock results of isothiazolone compositions of Example 1 , Comparative Example 1 , and a Control according to Experiment 1.
  • Fig. 2 is a photograph showing salt shock results of 10-fold dilutions of the isothiazolone compositions of Example 1 and Comparative Example 1 according to Experiment 1.
  • R-i and R 2 are independently a hydrogen atom, a halogen atom, or a C C alkyl group or aryl group;
  • the (a) 3-isothiazolone compound of the above Chemical Formula 1 is preferably contained in an amount of 0.1 to 20 wt% in the isothiazolone composition of the present invention. If the content of the (a) 3- isothiazolone compound is less than 0.1 wt%, the resulting isothiazolone composition cannot be commercially used because of a low content of sterilizer. And, if the content exceeds 20 wt%, stability becomes deteriorated.
  • the isothiazolone composition of the present invention comprises an alkali metal nitrate salt as a stabilizer, instead of an alkali earth metal salt of a divalent metal such as magnesium nitrate that has been predominantly used as a stabilizer in an isothiazolone composition of the prior art, salt shock is inhibited which makes the isothiazolone composition stable.
  • Magnesium oxide which has been widely used as a pH neutralizing agent of an isothiazolone composition, reacts in the composition to exist in the form of MgCI2 (magnesium chloride). If the content of the MgCI2 exceeds 9 wt% of the composition, solubility of magnesium chloride decreases to cause precipitation of magnesium chloride itself, and more seriously, divalent metal magnesium causes salt shock and thus the aqueous polymer dispersion cannot be stabilized.
  • the (e) iodic acid, periodic acid, iodate, periodate, or a mixture thereof is preferably contained in an amount of 0.0001 to 0.01 wt% of the isothiazolone composition, more preferably 0.001 to 0.005 wt%. If the content is less than 0.0001 wt%, precipitation of the isothiazolone compound cannot be effectively prevented, and if it exceeds 0.01 wt%, production cost increases, thus making the composition uneconomical.
  • the (f) metal bromic acid salt is preferably selected from a group consisting of sodium bromate, potassium bromate and a mixture thereof.
  • the (g) chlorite salt, the other precipitation-preventing agent is preferably contained in an amount of 0.001 to 10 wt%, more preferably 0.01 to 1.0 wt%, and most preferably 0.05 to 0.2 wt%. If the content is less than 0.001 wt%, precipitation of the isothiazolone cannot be effectively prevented, and if it exceeds 10 wt%, the production cost increases, thus making the composition uneconomical.
  • the isothiazolone composition of the present invention preferably comprises (a) 0. to 20 wt% of a 3-isothiazolone compound; (b) 0.1 to 25 wt% of an alkali metal nitrate salt; (c) 0.001 to 20 wt% of an alkali metal chloride salt; and (d) a solvent making up the balance, and the three kinds of precipitation-preventing agents of (e), (f), and (g) alone or in combination.
  • the three kinds of precipitation- preventing agents preferably comprise (e) 0.0001 to 0.01 wt% of iodic acid, periodic acid, iodate, periodate, or a mixture thereof; (f) 0.01 to 1.0 wt% of a metal bromic acid salt; and (g) 0.001 to 10 wt% of chlorite salt.
  • the present invention also provides a method for stabilizing the isothiazolone composition
  • a method for stabilizing the isothiazolone composition comprising the step of (i) adding (a) 0.1 to 20 wt% of a 3-isothiazolone compound represented by the following Chemical Formula 1 ; (b) 0.1 to 25 wt% of an alkali metal nitrate salt; and (c) 0.001 to 20 wt% of an alkali metal carbonate salt to (d) a solvent making up the balance, to prepare a mixed solution of the isothiazolone composition: [Chemical Formula 1]
  • Ri and R 2 are independently a hydrogen atom, a halogen atom, or a C* ⁇ -C 4 alkyl group or aryl group; and, R 3 is a hydrogen atom, a C* ⁇ -C ⁇ 8 alkyl group, a C 2 -C- ⁇ s alkenyl group, a C 2 -Ci 8 alkinyl group, a C 3 -C ⁇ 2 cycloalkyl group having trigonal to ocgonal rings, a C ⁇ 0 -C 24 aralkyl group, or a C* ⁇ 0 -C 24 aryl group.
  • the (a) 3-isothiazolone compound is preferably selected from a group consisting of 5-chloro-2-methyl-4-isothiazolin-3-on, 2-methyl-4- isothiazolin-3-on, 4,5-dichloro-2-methyl-4-isothiazolin-3-on, 5-chloro-2-n- octyl-3-isothiazolone, 4,5-dichloro-2-n-octyl-3-isothiazolone, benzisothiazolone, or a mixture thereof.
  • the (c) alkali metal carbonate salt is added as a pH-neutralizing agent.
  • the introduced alkali metal carbonate salt reacts with chloric acid in the isothiazolone composition to exist in the form of an alkali metal chloride salt.
  • the (c) alkali metal carbonate is preferably introduced in an amount of 0.01 to 15 wt% of the isothiazolone composition, more preferably 0.1 to 10 wt%.
  • the (d) solvent is preferably selected from a group consisting of water, ethyleneglycol, propyleneglycol, dipropyleneglycol, polypropyleneglycol, diethyleneglycol, triethyleneglycol, 1 ,5-pentanediol, 2,4-pentanediol, benzyl alcohol or a mixture thereof.
  • the method for stabilizing isothiazolone further adds a compound selected from a group consisting of (e) iodic acid, periodic acid, iodate, periodate or a mixture thereof; (f) a metal bromate; (g) chlorite salt, and a mixture thereof to the isothiazolone composition as a precipitation-preventing agent to further stabilize the isothiazolone composition.
  • a compound selected from a group consisting of (e) iodic acid, periodic acid, iodate, periodate or a mixture thereof; (f) a metal bromate; (g) chlorite salt, and a mixture thereof to the isothiazolone composition as a precipitation-preventing agent to further stabilize the isothiazolone composition.
  • the mixture of two or more kinds of precipitation-preventing agents, which have different operation mechanisms, are preferably added in appropriate ratios.
  • the (e) iodic acid, periodic acid, iodate, periodate, or a mixture thereof is preferably added in an amount of 0.0001 to 0.01 wt% of the isothiazolone composition, more preferably 0.001 to 0.005 wt%. If the content is less than 0.0001 wt%, precipitation of isothiazolone cannot be effectively prevented, and if it exceeds 0.01 wt%, the color changes with the passage of time, and production cost increases thus making the method uneconomical.
  • the (e) iodic acid, periodic acid, iodate, periodate or a mixture thereof is preferably selected from a group consisting of lithium iodate, sodium iodate, potassium iodate, ammonium iodate, lithium periodate, sodium periodate, potassium periodate, ammonium periodate, iodic acid, periodic acid dihydrate or a mixture thereof, and iodic acid, periodic acid dihydrate, sodium iodic acid, potassium iodic acid or a mixture thereof are more preferable.
  • the isothiazolone composition of the present invention can be stably used in a dispersion or emulsion such as paint acrylate or latex, etc. because it does not comprise a divalent metal alkali earth metal salt such as magnesium chloride, which causes salt shock, therefore effectively inhibiting the growth of harmful microorganisms.
  • the isothiazolone composition of the present invention can be used for a microorganism inhibitor in microorganism habitats such as a cooling water tower, an air washer, a boiler, a mineral slurry, a wastewater disposal plant, a decorative fountain, a reversed osmotic filtration system, an ultrafiltration system, ballast water, an evaporation condenser, a heat exchanger, and for pulp and paper processing oils, plastics, emulsions and dispersants, paint, latex, coating agents metal processing oils, etc., to effectively inhibit the growth of harmful microorganisms such as bacteria, mold, algae, etc.
  • a microorganism inhibitor in microorganism habitats such as a cooling water tower, an air washer, a boiler, a mineral slurry, a wastewater disposal plant, a decorative fountain, a reversed osmotic filtration system, an ultrafiltration system, ballast water, an evaporation condenser, a heat exchanger, and for pulp and paper processing oils
  • 3-isothiazolone solutions were prepared with the compositions and contents given in the following Table 1.
  • 3- isothiazolone compound a mixture of 5-chloro-2-methyl-4-isothiazolin-3-on (CMI) and 2-methyl-4-isothiazolin-3-on (Ml) with the mixing ratio of approximately 3:1 was used.
  • the alkali metal carbonate (sodium chloride, potassium chloride) and magnesium chloride are those produced in the composition by sodium carbonate, potassium carbonate, magnesium nitrate and magnesium oxide introduced for pH neutralization.
  • an isothiazolone composition causing salt shock comprises many magnesium ions as a stabilizer. It was confirmed whether or not samples prepared according to Examples 1 to 13 and Comparative Example 1 can be used as a sterilizer for a dispersion or emulsion such as paint acrylate or latex, etc. that sensitively reacts with divalent ions and coagulates, that is, whether or not they can stabilize a polymer aqueous dispersion.
  • Fig. 2 is a photo showing the salt shock results of 10- fold dilutions of isothiazolone composition samples of Example 1, and Comparative Example 1 in Experiment 1.
  • the isothiazolone composition that does not comprise an alkali earth metal salt of a divalent metal such as magnesium chloride that is, an isothiazolone composition stabilized by an alkali metal nitrate salt, can stabilize a polymer aqueous dispersion of a high concentration.
  • Fig. 3 is a photo showing the salt shock results of isothiazolone composition samples of Example 1 and Comparative Example 1.
  • the sample of Comparative Example 1 showed a large change in concentration of main ingredients after being stored at 65 ° C for 28 days, thus the ratio of CMI/MI decreased and precipitate formed. Since, of the two main ingredients of the isothiazolone solution, i.e. CMIT and MIT, the stability of CMIT is lower than that of MIT, the result that the initial ratio of 3:1 decreased means that CMI precipitated by the amount of decrease.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

The present invention relates to an isothiazolone composition and a method for stabilizing the same, and particularly to an isothiazolone composition that does not comprise alkali earth metal salt of a divalent metal such as magnesium chloride, which causes salt shock, and thus that can be stably used as a sterilizer in a dispersion or emulsion such as paint acrylate or latex, therefore effectively preventing growth of microorganisms, and that has superior storage stability due to its low precipitation formation rate because it comprises a precipitation-preventing agent, and a method for stabilizing the same.

Description

ISOTHIAZOLONE COMPOSITION AND METHOD FOR STABILIZING
ISOTHIAZOLONE
BACKGROUND OF THE INVENTION (a) Field of the Invention
The present invention relates to an isothiazolone composition and a method for stabilizing the same, and more specifically to an isothiazolone composition that does not comprise a divalent alkali earth metal salt such as magnesium chloride, which causes salt shock, and thus can be stably used for a sterilizer in a dispersion or an emulsion such as paint acrylate or latex, etc., therefore effectively preventing the growth of microorganisms, and that has superior storage stability due to its low rate of precipitation formation. (b) Description of the Related Art Isothiazolone, which has extensive sterilizing activity for many harmful organisms originating from animals and plants such as bacteria, mold, algae, etc., is added to cosmetics, paints, etc. as an inhibitor for the growth of harmful microorganisms.
However, since isothiazolone is decomposed in a polar organic solvent such as alcohol, or in water, its biological activity deteriorates with the passage of time. Therefore, many studies for increasing stability of isothiazolone in a polar organic solvent or water have been conducted.
In order to increase stability of isothiazolone in a polar organic solvent or water, US Patent No. 3,870,785 has suggested a method of adding a metal nitrate salt, a nitrite salt, etc. to the composition as a stabilizer. And, US Patent No. 4,165,318 has suggested a method of adding formaldehyde or a formaldehyde-eluting material to an isothiazolone composition as a stabilizer. In addition, US Patent No. 4,824,957 has suggested a method of adding an organic hydroxylic solvent to an isothiazolone composition as a stabilizer.
However, for various reasons, it is preferable to reduce the amount of the stabilizer used for stabilizing a sterilizer comprising an isothiazolone compound.
For example, a dispersion or an emulsion such as paint acrylate or latex, etc., which requires prevention of change and decomposition by microorganisms, sensitively reacts with a salt, and particularly, it does not mix well with a sterilizer comprising salts of divalent ions which cause coagulation. Moreover, sterilization active ingredients may be incorporated into the coagulation, thus the sterilization active ingredient may be reduced or removed if a product to be stored is filtered.
At present, a metal nitrate salt, particularly magnesium chloride or magnesium nitrate, is added to a 3-isothiazolone composition as a stabilizer. A commonly used isothiazolone composition comprises 1 to 20 wt% of isothiazolone and 15 to 25 wt% of a nitrate salt.
In addition, isothiazolone compositions comprise divalent metal, particularly magnesium oxide, as a pH-neutralizing agent. However, an isothiazolone composition comprising a substantial amount of a divalent metal salt such as magnesium oxide cannot be preferably used for a sterilizer because it has a problem due to "salt shock" of bivalent metal salts. SUMMARY OF THE INVENTION
The present invention relates to an isothiazolone composition and a method for stabilizing the same, and more specifically to an isothiazolone composition that does not comprise a divalent alkali earth metal salt such as magnesium chloride, which causes salt shock, and thus that can be stably used for a sterilizer in a dispersion or an emulsion such as paint acrylate or latex, etc., therefore effectively preventing the growth of microorganisms, and that has superior storage stability due to its low rate of precipitation formation.
BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 is a photograph showing salt shock results of isothiazolone compositions of Example 1 , Comparative Example 1 , and a Control according to Experiment 1.
Fig. 2 is a photograph showing salt shock results of 10-fold dilutions of the isothiazolone compositions of Example 1 and Comparative Example 1 according to Experiment 1.
Fig. 3 is a photograph showing salt shock results of isothiazolone compositions of Example 1 and Comparative Example 1 according to Experiment 2 (paint acrylate emulsion). Fig. 4 is a photograph showing the salt shock results of the isothiazolone compositions of Example 1 and Comparative Example 1 according to Experiment 3 (latex emulsion).
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention is made to solve the above-mentioned problems, and it is an object of the present invention to provide an isothiazolone composition that does not comprise an alkali earth metal salt of a divalent metal such as magnesium chloride, which causes salt shock, and thus can be stably used for a microorganism inhibitor in a dispersion or an emulsion such as paint acrylate or latex, etc., therefore effectively preventing the growth of harmful microorganisms, and that has superior storage stability because it comprises appropriate ratios of three kinds of stabilizers having synergy for increasing stability of an isothiazolone solution, and thus has a low rate of precipitation formation even at a much lower concentration than those disclosed in the prior art.
It is another object of the present invention to provide a method for stabilizing isothiazolone.
In order to achieve these objects, the present invention provides an isothiazolone composition comprising (a) a 3-isothiazolone compound represented by the following Chemical Formula 1 ; (b) an alkali metal nitrate salt; (c) an alkali metal chloride salt; and (d) a solvent: [Chemical Formula 1]
In the above Chemical Formula 1,
R-i and R2 are independently a hydrogen atom, a halogen atom, or a C C alkyl group or aryl group; and,
R3 is a hydrogen atom, a Cι-C-|8 alkyl group, a C2-Cιs alkenyl group, a C2-Cis alkinyl group, a C3-Cι2 cycloalkyl group having trigonal to octagonal rings, a C10-C24 aralkyl group, or a Cι0-C2 aryl group.
The present invention also provides a method for stabilizing isothiazolone comprising the step of adding (a) 0.1 to 20 wt% of a 3- isothiazolone compound represented by the above Chemical Formula 1; (b) 0.1 to 25 wt% of an alkali metal nitrate salt; and (c) 0.001 to 20 wt% of an alkali metal carbonate salt to (d) a solvent making up the balance to prepare a mixed solution: [Chemical Formula 1]
In the above Chemical Formula 1,
Ri and R2 are independently a hydrogen atom, a halogen atom, or a Cι-C alkyl group or aryl group; and,
R3 is a hydrogen atom, a CrC18 alkyl group, a C2-C18 alkenyl group, a C2-Ci8 alkinyl group, a C3-C*ι2 cycloalkyl group having trigonal to octagonal rings, a C10-C24 aralkyl group, or a Cιo-C24 aryl group. The present invention will now be explained in detail. The present invention is characterized by comprising (a) a 3- isothiazolone compound represented by the following Chemical Formula 1 ; (b) an alkali metal nitrate salt; (c) an alkali metal chloride salt; and (d) a solvent as essential ingredients: [Chemical Formula 1]
In the above Chemical Formula 1 , Ri and R2 are independently a hydrogen atom, a halogen atom, a
C C4 alkyl group or aryl group;
R3 is a hydrogen atom, a Cι-Cι8 alkyl group, a C2-C*ι8 alkenyl group, a C2-C-i8 alkinyl group, a C3-d2 cycloalkyl group having trigonal to octagonal rings, a Cι0-C24 aralkyl group, or C*ι0-C24 aryl group. The (a) 3-isothiazolone compound, which has extensive sterilizing activity for many harmful microorganisms originating from animals and plants such as bacteria, mold, algae, etc., is added to cosmetics, paints, etc. to be used for an inhibitor for growth of harmful microorganisms.
The (a) 3-isothiazolone compound of the above Chemical Formula 1 is preferably contained in an amount of 0.1 to 20 wt% in the isothiazolone composition of the present invention. If the content of the (a) 3- isothiazolone compound is less than 0.1 wt%, the resulting isothiazolone composition cannot be commercially used because of a low content of sterilizer. And, if the content exceeds 20 wt%, stability becomes deteriorated.
As the (a) 3-isothiazolone compound, 5-chloro-2-methyl-4- isothiazolin-3-on, 2-methyl-4-isothiazolin-3-on, 4,5-dichloro-2-methyl-4- isothiazolin-3-on, 5-chloro-n-octyl-3-isothiazolone, 4,5-dichloro-2-n-octyl-3- isothiazolone, benzisothiazolone or a mixture thereof can be preferably used.
In case the mixture of the (a) 3-isothiazolone compound of Chemical Formula 1 is used, the mixture of 5-chloro-2-methyl-4- isothiazolonin-3-on and 2-methyl-4-isothiazolin-3-on is preferable, and the mixing ratio thereof is preferably 1 : 20 to 20 : 1. In addition, the isothiazolone composition of the present invention comprises the (b) alkali metal nitrate salt as a stabilizer for preventing decomposition of isothiazolone.
In order to prevent formation of a precipitation of the isothiazolone composition, a metal nitrate salt has been widely used, generally magnesium nitrate. However, if the content of the magnesium nitrate is less than 0.1 wt% of the isothiazolone composition, precipitation-preventing effects cannot be anticipated, and if it exceeds 25 wt%, solubility of magnesium nitrate decreases to cause precipitation of magnesium nitrate itself, and worse, divalent ion magnesium causes salt shock and thus aqueous polymer dispersion cannot be stabilized.
However, since the isothiazolone composition of the present invention comprises an alkali metal nitrate salt as a stabilizer, instead of an alkali earth metal salt of a divalent metal such as magnesium nitrate that has been predominantly used as a stabilizer in an isothiazolone composition of the prior art, salt shock is inhibited which makes the isothiazolone composition stable.
The content of the (b) alkali metal nitrate salt is preferably 0.1 to 25 wt% of the isothiazolone composition. If the content is less than 0.1 wt%, precipitation of isothiazolone cannot be effectively prevented, and if it exceeds 25 wt%, solubility decreases and product cost increases, making the composition uneconomical.
As the (b) alkali metal nitrate salt, lithium nitrate, sodium nitrate, potassium nitrate, or a mixture thereof can be preferably used, and sodium nitrate is most preferable.
In addition, the isothiazolone composition of the present invention comprises (c) an alkali metal chloride salt that is produced by the reaction of an alkali metal introduced as a pH neutralizing agent with chloric acid.
Magnesium oxide, which has been widely used as a pH neutralizing agent of an isothiazolone composition, reacts in the composition to exist in the form of MgCI2 (magnesium chloride). If the content of the MgCI2 exceeds 9 wt% of the composition, solubility of magnesium chloride decreases to cause precipitation of magnesium chloride itself, and more seriously, divalent metal magnesium causes salt shock and thus the aqueous polymer dispersion cannot be stabilized.
However, since the isothiazolone composition of the present invention comprises an alkali metal carbonate salt as a pH- neutralizing agent, instead of magnesium oxide that has been predominantly used as a pH-neutralizing agent of an isothiazolone composition, salt shock is prevented.
The (c) alkali metal chloride salt is preferably contained in an amount of 0.001 to 20 wt% of the isothiazolone composition, more preferably in an amount of 0.01 to 15 wt%, and most preferably 0.1 to 10 wt%. If the content is less than 0.001 wt%, the pH of the resulting isothiazolone composition cannot be controlled within a commercially acceptable range because the concentration of the alkali metal carbonate salt introduced as a pH-neutralizing agent is too low, and if the content exceeds 20 wt%, stability of the composition decreases and product cost increases, thus making the composition uneconomical.
The (c) alkali metal chloride salt is preferably sodium chloride, or potassium chloride with an alkali metal carbonate salt introduced thereto, or a mixture thereof. The alkali metal carbonate salt introduced as a pH- neutralizing agent is preferably sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, or a mixture thereof. In addition, the isothiazolone composition comprises a (d) solvent.
As the solvent, water, ethyleneglycol, propyleneglycol, dipropyleneglycol, polypropyleneglycol, diethyleneglycol, triethyleneglycol, 1 ,5-pentanediol, 2,4-pentanediol, benzyl alcohol or a mixture thereof can be preferably used. As another preferred embodiment of the present invention, the isothiazolone composition of the present invention may further comprise (e) iodic acid, periodic acid, iodate, periodate or a mixture thereof; (f) a metal bromic acid; and (g) chlorite salt, alone or in combination of appropriate ratios, as a stabilizer for preventing the decomposition of isothiazolone. More preferably, a combination of the three kinds of precipitation- preventing agents is added.
In addition, during the storage of the isothiazolone composition, a small amount of precipitation, which is different from that of salt shock, forms due to the decomposition of by-products during the production process and compounds produced during storage. The precipitation is commercially unfavorable because it damages the appearance of the product.
However, the present invention can effectively inhibit the precipitation by introducing a small amount of a mixture of three kinds of additives having superior effects for inhibiting formation of a precipitation to the isothiazolone composition. Specifically, the isothiazolone composition can be more effectively stabilized by using a mixture of compounds selected from a group consisting of (e) iodic acid, periodic acid, iodate salt, periodate salt, or a mixture thereof; (f) a metal bromic acid salt; and (g) chlorite salt, than by using the compound of (e), (f), and (g) alone.
The (e) iodic acid, periodic acid, iodate, periodate, or a mixture thereof is preferably contained in an amount of 0.0001 to 0.01 wt% of the isothiazolone composition, more preferably 0.001 to 0.005 wt%. If the content is less than 0.0001 wt%, precipitation of the isothiazolone compound cannot be effectively prevented, and if it exceeds 0.01 wt%, production cost increases, thus making the composition uneconomical.
The (e) iodic acid, periodic acid, iodate, periodate, or a mixture thereof is preferably selected from a group consisting of lithium iodate, sodium iodate, potassium iodate, ammonium iodate, lithium periodate, sodium periodate, potassium periodate, ammonium periodate, iodic acid, periodic acid dihydrate, or a mixture thereof, and more preferably iodic acid, periodic acid dihydrate, sodium iodic acid, potassium iodic acid or a mixture thereof. The (f) metal bromic acid, the other precipitation-preventing agent, is preferably contained in an amount of 0.001 to 1.0 wt% of the isothiazolone composition, more preferably 0.01 to 0.2 wt%. If the content is less than 0.001 wt%, precipitation of isothiazolone cannot be effectively prevented, and if it exceeds 1.0 wt%, production cost increases, thus making the composition uneconomical.
The (f) metal bromic acid salt is preferably selected from a group consisting of sodium bromate, potassium bromate and a mixture thereof. In addition, the (g) chlorite salt, the other precipitation-preventing agent, is preferably contained in an amount of 0.001 to 10 wt%, more preferably 0.01 to 1.0 wt%, and most preferably 0.05 to 0.2 wt%. If the content is less than 0.001 wt%, precipitation of the isothiazolone cannot be effectively prevented, and if it exceeds 10 wt%, the production cost increases, thus making the composition uneconomical.
The (g) chlorite salt is preferably sodium chlorite, potassium chlorite or a mixture thereof.
The isothiazolone composition of the present invention preferably comprises (a) 0. to 20 wt% of a 3-isothiazolone compound; (b) 0.1 to 25 wt% of an alkali metal nitrate salt; (c) 0.001 to 20 wt% of an alkali metal chloride salt; and (d) a solvent making up the balance, and the three kinds of precipitation-preventing agents of (e), (f), and (g) alone or in combination. The three kinds of precipitation- preventing agents preferably comprise (e) 0.0001 to 0.01 wt% of iodic acid, periodic acid, iodate, periodate, or a mixture thereof; (f) 0.01 to 1.0 wt% of a metal bromic acid salt; and (g) 0.001 to 10 wt% of chlorite salt.
The present invention also provides a method for stabilizing the isothiazolone composition comprising the step of (i) adding (a) 0.1 to 20 wt% of a 3-isothiazolone compound represented by the following Chemical Formula 1 ; (b) 0.1 to 25 wt% of an alkali metal nitrate salt; and (c) 0.001 to 20 wt% of an alkali metal carbonate salt to (d) a solvent making up the balance, to prepare a mixed solution of the isothiazolone composition: [Chemical Formula 1]
In the above Chemical Formula 1,
Ri and R2 are independently a hydrogen atom, a halogen atom, or a C*ι-C4 alkyl group or aryl group; and, R3 is a hydrogen atom, a C*ι-Cι8 alkyl group, a C2-C-ιs alkenyl group, a C2-Ci8 alkinyl group, a C3-Cι2 cycloalkyl group having trigonal to ocgonal rings, a Cι0-C24 aralkyl group, or a C*ι0-C24 aryl group.
The (a) 3-isothiazolone compound is preferably selected from a group consisting of 5-chloro-2-methyl-4-isothiazolin-3-on, 2-methyl-4- isothiazolin-3-on, 4,5-dichloro-2-methyl-4-isothiazolin-3-on, 5-chloro-2-n- octyl-3-isothiazolone, 4,5-dichloro-2-n-octyl-3-isothiazolone, benzisothiazolone, or a mixture thereof.
According to the method for stabilizing isothiazolone of the present invention, the (c) alkali metal carbonate salt is added as a pH-neutralizing agent. The introduced alkali metal carbonate salt reacts with chloric acid in the isothiazolone composition to exist in the form of an alkali metal chloride salt.
The (c) alkali metal carbonate is preferably introduced in an amount of 0.01 to 15 wt% of the isothiazolone composition, more preferably 0.1 to 10 wt%.
The (c) alkali metal carbonate is preferably sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate or a mixture thereof.
In addition, the (d) solvent is preferably selected from a group consisting of water, ethyleneglycol, propyleneglycol, dipropyleneglycol, polypropyleneglycol, diethyleneglycol, triethyleneglycol, 1 ,5-pentanediol, 2,4-pentanediol, benzyl alcohol or a mixture thereof.
As another preferred embodiment of the present invention, the method for stabilizing isothiazolone further adds a compound selected from a group consisting of (e) iodic acid, periodic acid, iodate, periodate or a mixture thereof; (f) a metal bromate; (g) chlorite salt, and a mixture thereof to the isothiazolone composition as a precipitation-preventing agent to further stabilize the isothiazolone composition. The mixture of two or more kinds of precipitation-preventing agents, which have different operation mechanisms, are preferably added in appropriate ratios.
The (e) iodic acid, periodic acid, iodate, periodate, or a mixture thereof is preferably added in an amount of 0.0001 to 0.01 wt% of the isothiazolone composition, more preferably 0.001 to 0.005 wt%. If the content is less than 0.0001 wt%, precipitation of isothiazolone cannot be effectively prevented, and if it exceeds 0.01 wt%, the color changes with the passage of time, and production cost increases thus making the method uneconomical. The (e) iodic acid, periodic acid, iodate, periodate or a mixture thereof is preferably selected from a group consisting of lithium iodate, sodium iodate, potassium iodate, ammonium iodate, lithium periodate, sodium periodate, potassium periodate, ammonium periodate, iodic acid, periodic acid dihydrate or a mixture thereof, and iodic acid, periodic acid dihydrate, sodium iodic acid, potassium iodic acid or a mixture thereof are more preferable.
The (f) metal bromate is preferably added in an amount of 0.001 to 1.0 wt% of the isothiazolone composition, more preferably 0.001 to 0.2 wt%. If the content is less than 0.001 wt%, precipitation of isothiazolone cannot be effectively prevented, and if it exceeds 0.2 wt%, production cost increases, thus making the method uneconomical. The (f) metal bromate is preferably selected from a group consisting of sodium bromate, potassium bromate and a mixture thereof.
The (g) chlorite salt is preferably added in an amount of 0.001 to 10 wt% of the isothiazolone composition, more preferably 0.01 to 1.0 wt%, and most preferably 0.05 to 0.2 wt%. If the content is less than 0.001 wt%, precipitation of isothiazolone cannot be effectively prevented, and if it exceeds 10 wt%, production cost increases, thus making the method uneconomical. The (g) chlorite salt is preferably selected from sodium chlorite, potassium chlorite and a mixture thereof.
As explained, the isothiazolone composition of the present invention can be stably used in a dispersion or emulsion such as paint acrylate or latex, etc. because it does not comprise a divalent metal alkali earth metal salt such as magnesium chloride, which causes salt shock, therefore effectively inhibiting the growth of harmful microorganisms.
Accordingly, the isothiazolone composition of the present invention can be used for a microorganism inhibitor in microorganism habitats such as a cooling water tower, an air washer, a boiler, a mineral slurry, a wastewater disposal plant, a decorative fountain, a reversed osmotic filtration system, an ultrafiltration system, ballast water, an evaporation condenser, a heat exchanger, and for pulp and paper processing oils, plastics, emulsions and dispersants, paint, latex, coating agents metal processing oils, etc., to effectively inhibit the growth of harmful microorganisms such as bacteria, mold, algae, etc.
The present invention will be explained with reference to the following Examples and Comparative Examples. However, these are intended to only illustrate the present invention and the present invention is not limited to them. Example
[Examples 1 to 13 and Comparative Example 1]
Concentrated 3-isothiazolone solutions were prepared with the compositions and contents given in the following Table 1. As the 3- isothiazolone compound, a mixture of 5-chloro-2-methyl-4-isothiazolin-3-on (CMI) and 2-methyl-4-isothiazolin-3-on (Ml) with the mixing ratio of approximately 3:1 was used.
As described in Table 1 , the samples of Examples 1 to 13 and Comparative Example 1 were prepared by mixing the 3-isothiazolone compound, sodium nitrate, sodium carbonate, magnesium nitrate (Comparative Example), magnesium oxide (Comparative Example), and water and adding KI03, NaBr03, and NaCI02 for preventing precipitation. [Table 1] (wt%)
In the above samples of Examples 1 to 13 and Comparative Example 1 , the alkali metal carbonate (sodium chloride, potassium chloride) and magnesium chloride are those produced in the composition by sodium carbonate, potassium carbonate, magnesium nitrate and magnesium oxide introduced for pH neutralization.
Specifically, the alkali metal carbonate (sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate) introduced as a pH-neutralizing agent exists in the form of an alkali metal chloride salt (NaCI, KCI) in the composition of the present invention. [Experiment 1] Salt Shock Test For samples prepared according to Examples 1 to 13 and Comparative Example 1 , whether or not salt shock is caused was examined and the results are described in the following Table 2.
Generally, an isothiazolone composition causing salt shock comprises many magnesium ions as a stabilizer. It was confirmed whether or not samples prepared according to Examples 1 to 13 and Comparative Example 1 can be used as a sterilizer for a dispersion or emulsion such as paint acrylate or latex, etc. that sensitively reacts with divalent ions and coagulates, that is, whether or not they can stabilize a polymer aqueous dispersion.
For testing, 5 ml of a detecting agent was added to 10 ml of isothiazolone solutions to be tested by droplets. And, as a salt shock detecting agent, a 5% sodium methasilicate aqueous solution (Na2Si03-9H20) was used. [Table 2]
As can be seen from the Table 2, the salt shock composition forms precipitation, and the non salt shock types did not form precipitation.
When adding 5 ml of the detecting agent to 10 ml of the sample of Comparative Example 1 , a white or gray precipitation formed. However, adding a detecting agent to the sample of Example 1 did not cause formation of a precipitation.
Accordingly, it can be identified that the sample of Comparative Example 1 is of a salt shock type, and that of Example 1 is of a non salt shock type.
In the above Experiment 1 , a salt free isothiazolone solution stabilized by a glycol solvent was used as a control.
Fig. 1 is a photo showing the salt shock results of isothiazolone composition samples of Example 1 , Comparative Example 1 , and a control, in Experiment 1.
In addition, Fig. 2 is a photo showing the salt shock results of 10- fold dilutions of isothiazolone composition samples of Example 1, and Comparative Example 1 in Experiment 1.
As shown in Fig. 1 , the sample of Comparative Example 1 formed a white or gray precipitation, and that of Example 1 did not form a precipitation. And, as shown in Fig. 2, the experiment with the 10-fold dilutions of samples of Example 1 and Comparative Example 1 showed the same results.
Accordingly, it was confirmed that the isothiazolone composition that does not comprise an alkali earth metal salt of a divalent metal such as magnesium chloride, that is, an isothiazolone composition stabilized by an alkali metal nitrate salt, can stabilize a polymer aqueous dispersion of a high concentration.
[Experiment 2]
Salt shock generation test in paint acrylate emulsion
Whether or not the samples of Examples 1 to 13 and Comparative Example 1 caused salt shock was examined by the same method as the
Experiment 1 , except that, in order for practical confirmation, after adding the samples of Examples 1 to 13 and Comparative Example 1 to a paint acrylate emulsion in a ratio of 5 ml : 10 ml, whether or not coagulation
(precipitation) occurred as as result of salt shock was examined and the results are described in the following Table 3. [Table 3]
As can be seen from the Table 3, the salt shock type composition coagulated (precipitation), but the non salt shock type compositions did not coagulate (precipitation).
The sample of Comparative Example 1 coagulated (precipitation) by salt shock when introduced in a polymer aqueous dispersion paint acrylate emulsion.
Accordingly, it can be confirmed that the sample of Comparative Example 1 is of a salt shock type, and those of Examples 1 to 13 are of non salt shock types. Fig. 3 is a photo showing the salt shock results of isothiazolone composition samples of Example 1 and Comparative Example 1.
As shown in Fig. 3, the paint acrylate emulsion into which the isothiazolone composition of Comparative Example 1 was introduced was seriously coagulated, and the paint acrylate emulsion into which the isothiazolone composition of Example 1 was introduced maintained a solution state without coagulation.
Accordingly, it can be identified that an isothiazolone composition that does not comprise an alkali earth metal salt of a divalent metal such as magnesium chloride, that is, an isothiazolone composition stabilized by an alkali metal nitrate salt can stabilize a polymer aqueous dispersion of a high concentration, and thus it can be used for a process such as let down during preparation of paint, to which the existing commercial products cannot be applied. [Experiment 3] Salt shock test in latex emulsion
Whether or not the samples of Examples 1 to 13 and Comparative Example 1 caused salt shock was examined by the same method in Experiment 1 , except that, for practical confirmation, after adding the samples of Examples 1 to 13 and Comparative Example 1 to a latex emulsion in a ratio of 5 ml : 10 ml, whether or not coagulation (precipitation) by salt shock occurred was examined and the results are presented in the following Table 4. [Table 4]
As can be seen from the Table 4, the salt shock type composition formed coagulation (precipitation), but the non salt shock type compositions did not form coagulation (no precipitation).
The sample of Comparative Example 1 formed coagulation (precipitation) by salt shock, when introduced in a polymer aqueous dispersion of latex emulsion. However, those of Examples 1 to 13 did not form coagulation (no precipitation).
Accordingly, it can be identified that the sample of Comparative Example 1 is of a salt shock type, but those of Examples 1 to 13 are of non salt shock types.
Fig. 4 is a photo showing the salt shock results of isothiazolone composition samples of Example 1 and Comparative Example 1 in Experiment 3.
As shown in Fig. 4, the latex emulsion into which the isothiazolone composition of Comparative Example 1 was introduced was seriously coagulated, and the latex emulsion into which the sample of Example 1 was introduced maintained a solution state without coagulation. [Experiment 4] Precipitation Formation Test For the samples prepared according to Examples 1 to 13 and
Comparative Example 1 , a storage stability test was conducted and the results are described in the following Table 5.
In order to confirm storage stability, the isothiazolone compositions (samples of Examples 1 to 13 and Comparative Example 1) were kept in an oven at 65 °C for 28 days, and the concentrations of main ingredients (MIT, CMIT) remaining in the compositions were analyzed using HLPC. The results are described in the following Table 5. [Table 5]
As can be seen from the Table 5, the sample of Comparative Example 1 showed a large change in concentration of main ingredients after being stored at 65°C for 28 days, thus the ratio of CMI/MI decreased and precipitate formed. Since, of the two main ingredients of the isothiazolone solution, i.e. CMIT and MIT, the stability of CMIT is lower than that of MIT, the result that the initial ratio of 3:1 decreased means that CMI precipitated by the amount of decrease.
Meanwhile, the samples of Examples 1 to 13, which were prepared by adding KI03, NaBr03, and NaCI02 as stabilizers, showed minor changes in concentrations of main ingredients after being stored for 28 days, and particularly when the mixture of KI03, NaBr03 and NaCI02 of appropriate ratios were added, there was little change of concentrations of main ingredients, and the ratio of CMI/MI was large, hence a stabilized isothiazolone composition in which precipitation does not occur could be obtained.
Accordingly, from the above experiment, it can be confirmed that a more stabilized 3-isothiazolone composition can be obtained by introducing a small amount of iodate, metal bromate, and chlorite in combination of appropriate ratios, compared to when using each of the compounds alone.
The isothiazolone compostion of the present invention can be stably used as a sterilizer in a dispersion or emulsion such as paint acrylate or latex, etc. because it does not include an alkali earth metal salt of a divalent metal such as magnesium chloride, which causes salt shock, and thus it can effectively inhibit growth of harmful microorganisms, and it has superior storage stability due to its low precipitation forming rate.

Claims

WHAT IS CLAIMED IS:
1. An isothiazolone composition comprising:
(a) a 3-isothiazolone compound represented by the following Chemical Formula 1 ;
(b) an alkali metal nitrate;
(c) an alkali metal chloride; and
(d) a solvent: [Chemical Formula 1]
wherein,
Ri and R2 are independently a hydrogen atom, a halogen atom, or a Cι-C alkyl group or aryl group;
R3 is a hydrogen atom, a C C-|8 alkyl group, a C2-C*i8 alkenyl group, a C2-C18 alkinyl group, a C3-Cι2 cycloalkyl group having trigonal to octagonal rings, a C10-C24 aralkyl group, or a Cι-C24 aryl group. 2. The isothiazolone composition according to Claim 1 , wherein the (a) 3- isothiazolone compound represented by the Chemical Formula 1 is selected from the group consisting of 5-chloro-2-methyl-4-isothiazolin-3-on,
2-methyl-4-isothiazolin-3-on, 4,5-dichloro-2-methyl-4-isothiazolin-3-on, 5- chloro-2-n-octyl-3-isothialzolone, 4,5-dichloro-2-n-octyl-3-isothiazolone and benzisothiazolone.
3. The isothiazolone composition according to Claim 1 , wherein the (b) alkali metal nitrate is selected from the group consisting of lithium nitrate, sodium nitrate and potassium nitrate.
4. The isothiazolone composition according to Claim 1 , wherein the (c) alkali metal chloride is selected from a group consisting of sodium chloride and potassium chloride.
5. The isothiazolone composition according to Claim 1, wherein the (d) solvent is selected from a group consisting of water, ethylene glycol, propyleneglycol, dipropyleneglycol, polypropyleneglycol, diethyleneglycol, triethyleneglycol, 1 ,5-pentanediol, 2,4-pentanediol and benzyl alcohol.
6. The isothiazolone composition according to Claim 1 , which comprises:
(a) 0.1 to 20 wt% of the 3-isothiazolone compound; (b) 0.1 to 25 wt% of the alkali metal nitrate;
(c) 0.001 to 20 wt% of the alkali metal chloride; and
(d) the solvent making up the balance.
7. The isothiazolone composition according to Claim 6, wherein the (c) alkali metal chloride is contained in an amount of 0.1 to 15 wt%, based on the weight of the isothiazolone composition.
8. The isothiazolone composition according to Claim 6, wherein the (c) alkali metal chloride is contained in an amount of 0.1 to 10 wt%, based on the weight of the isothiazolone composition.
9. The isothiazolone composition according to Claim 1 , which further comprises a precipitation-preventing agent selected from a group consisting of (e) iodic acid, periodic acid, iodate, periodate or a mixture thereof; (f) metal bromate; and (g) chlorite.
10. The isothiazolone composition according to Claim 9, wherein the (e) iodic acid, periodic acid, iodate, periodate, or a mixture thereof is contained in an amount of 0.0001 to 0.01 wt%, based on the weight of the isothiazolone composition.
11. The isothiazolone composition according to Claim 9, wherein the (e) iodic acid, periodic acid, iodate, periodate or a mixture thereof is contained in an amount of 0.001 to 0.005 wt%, based on the weight of the isothiazolone composition.
12. The isothiazolone composition according to Claim 9, wherein the (f) metal bromate is contained in an amount of 0.001 to 1.0 wt%, based on the weight of the isothiazolone composition.
13. The isothiazolone composition according to Claim 9, wherein the (f) metal bromate is contained in an amount of 0.001 to 0.2 wt%, based on the weight of the isothiazolone composition.
14. The isothiazolone composition according to Claim 9, wherein the (g) chlorite is contained in an amount of 0.001 to 10 wt%, based on the weight of the isothiazolone composition.
15. The isothiazolone composition according to Claim 9, wherein the (g) chlorite is contained in an amount of 0.01 to 1 wt%, based on the weight of the isothiazolone composition.
16. The isothiazolone composition according to Claim 9, wherein the (g) chlorite is contained in an amount of 0.05 to 0.2 wt%, based on the weight of the isothiazolone composition.
17. The isothiazolone composition according to Claim 9, wherein the (e) iodic acid, periodic acid, iodate, periodate or a mixture thereof is selected from a group consisting of lithium iodate, sodium iodate, potassium iodate, ammonium iodate, lithium periodate, sodium periodate, potassium periodate, ammonium periodate, iodic acid, periodic acid dihydrate and a mixture thereof.
18. The isothiazolone composition according to Claim 9, wherein the (f) metal bromate is sodium bromate or potassium bromate.
19. The isothiazolone composition according to Claim 9, wherein the (g) chlorite is sodium chlorite or potassium chlorite.
20. A method for stabilizing isothiazolone comprising the step of adding (a) 0.1 to 20 wt% of a 3-isothiazolone compound represented by the following Chemical Formula 1 ; (b) 0.1 to 25 wt% of an alkali metal nitrate ; and (c ) 0.001 to 20 wt% of an alkali metal carbonate, to (d) a solvent making up the balance, to prepare a mixed solution: [Chemical Formula 1]
wherein,
Ri and R2 are independently a hydrogen atom, a halogen atom, or a C1-C4 alkyl group or aryl group;
R3 is a hydrogen atom, a Cι-C-|8 alkyl group, a C2-C18 alkenyl group, a C2-Cιs alkinyl group, a C3-C-ι2 cycloalkyl group having trigonal to octatonal rings, a C10-C24 aralkyl group, or a Cι0-C24 aryl group.
21. The method for stabilizing isothiazolone according to Claim 20, wherein the (a) 3-isothiazolone compound of the Chemical Formula 1 is selected from a group consisting of 5-chloro-2-methyl-4-isothiazolin-3-on, 2-methyl- 4-isothiazolin-3-on, 4,5-dichloro-2-methyl-4-isothiazolin-3-on, 5-chloro-2-n- octyl-3-isothiazolone, 4,5-dichloro-2-n-octyl030isothiazolone and benzisothiazolone.
22. The method for stabilizing isothiazolone according to Claim 20, wherein the (b) alkali metal nitrate is selected from a group consisting of lithium nitrate, sodium nitrate and potassium nitrate.
23. The method for stabilizing isothiazolone according to Claim 20, wherein the (c ) alkali metal carbonate is selected from a group consisting of sodium carbonate, potassium carbonate, sodium bicarbonate and potassium bicarbonate.
24. The method for stabilizing isothiazolone according to Claim 20, wherein the (d) solvent is selected from a group consisting of water, ethyleneglycol, propyleneglycol, dipropyleneglycol, polypropyleneglycol, diethyleneglycol, triethylenegrlycol, 1 ,5-pentanediol, 2,4-pentanediol and benzyl alcohol.
25. The method for stabilizing isothiazolone according to Claim 20, wherein the (c) alkali metal carbonate is contained in an amount of 0.01 to 15 wt%, based on the weight of the isothiazolone composition.
26. The method fro stabilizing isothiazolone according to Claim 20, wherein the c) alkali metal carbonate is contained in an amount of 0.1 to 10 wt%, based on the weight of the isothiazolone composition.
27. The method for stabilizing isothiazolone according to Claim 20, which further comprises the step of adding a precipitation-preventing agent selected from a group consisting of (e) iodic acid, periodic acid, iodate, periodate and a mixture thereof; (f) metal bromate; and (g) chlorite, to the mixed solution.
28. The method for stabilizing isothiazolone according to Claim 27, wherein the (e) iodic acid, periodic acid, iodate, periodate or a mixture thereof is contained in an amount of 0.0001 to 0.01 wt% , based on the weight of the isothiazolone composition.
29. The method for stabilizing isothiazolone according to Claim 27, wherein the (e) iodic acid, periodic acid, iodate, periodate, or a mixture thereof is contained in an amount of 0.001 to 0.005 wt% , based on the weight of the isothiazolone composition.
30. The method for stabilizing isothiazolone according to Claim 27, wherein the (f) metal bromate is contained in an amount of 0.001 to 1.0 wt%, based on the weight of the isothiazolone composition.
31. The method for stabilizing isothiazolone according to Claim 27, wherein the (f) metal bromate is contained in an amount of 0.001 to 0.2 wt%, based on the weight of the isothiazolone composition.
32. The method for stabilizing isothiazolone according to Claim 27, wherein the (g) chlorite is contained in an amount of 0.001 to 10 wt%, based on the weight of the isothiazolone composition.
33. The method for stabilizing isothiazolone according to Claim 27, wherein the (g) chlorite is contained in an amount of 0.01 to 1 wt%, based on the weight of the isothiazolone composition.
34. The method for stabilizing isothiazolone according to Claim 27, wherein the (g) chlorite is contained in an amount of 0.05 to 0.2 wt%, based on the weight of the isothiazolone composition.
35. The method for stabilizing isothiazolone according to Claim 27, wherein the (e) iodic acid, periodic acid, iodate, periodate or a mixture thereof is selected from a group consisting of lithium iodate, sodium iodate, potassium iodate, ammonium iodate, lithium periodate, sodium periodate, potassium periodate, ammonium periodate, iodic acid, periodic acid dihydrate or a mixture thereof.
36. The method for stabilizing isothiazolone according to Claim 27, wherein the (f) metal bromate is sodium bromate or potassium bromate.
37. The method for stabilizing isothiazolone according to Claim 27, wherein the (g) chlorite is sodium chlorite or potassium chlorite.
EP03755296A 2002-05-29 2003-05-28 Isothiazolone composition and method for stabilizing isothiazolone Withdrawn EP1507771A4 (en)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
KR2002030023 2002-05-29
KR20020030023 2002-05-29
KR2002062096 2002-10-11
KR1020020062096A KR20030093086A (en) 2002-05-29 2002-10-11 Isothiazolone composition and method for stabilizing isothiazolone
KR1020020076857A KR20030093087A (en) 2002-05-29 2002-12-05 Isothiazolone composition and method for stabilizing isothiazolone
KR2002076857 2002-12-05
KR1020030018625A KR100975373B1 (en) 2002-05-29 2003-03-25 Isothiazolone composition and method for stabilizing isothiazolone
KR2003018624 2003-03-25
KR2003018625 2003-03-25
KR1020030018624A KR100975372B1 (en) 2002-05-29 2003-03-25 Isothiazolone composition and method for stabilizing isothiazolone
KR2003028973 2003-05-07
KR1020030028974A KR100975375B1 (en) 2002-05-29 2003-05-07 Isothiazolone composition and method for stabilizing isothiazolone
KR2003028974 2003-05-07
KR1020030028973A KR100975374B1 (en) 2002-05-29 2003-05-07 Isothiazolone composition and method for stabilizing isothiazolone
PCT/KR2003/001047 WO2003099799A1 (en) 2002-05-29 2003-05-28 Isothiazolone composition and method for stabilizing isothiazolone

Publications (2)

Publication Number Publication Date
EP1507771A1 true EP1507771A1 (en) 2005-02-23
EP1507771A4 EP1507771A4 (en) 2006-08-30

Family

ID=29587971

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03755296A Withdrawn EP1507771A4 (en) 2002-05-29 2003-05-28 Isothiazolone composition and method for stabilizing isothiazolone

Country Status (5)

Country Link
EP (1) EP1507771A4 (en)
JP (1) JP2005527626A (en)
CN (1) CN100400521C (en)
AU (1) AU2003232654B2 (en)
WO (1) WO2003099799A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5194205B2 (en) * 2004-02-19 2013-05-08 住化エンビロサイエンス株式会社 Industrial antibacterial composition
JP5101826B2 (en) * 2006-02-28 2012-12-19 日本曹達株式会社 Water-soluble preparation containing isothiazolone compound and method for stabilizing isothiazolone compound
AU2007202261B2 (en) * 2006-06-02 2012-06-28 Rohm And Haas Company Microbicidal composition
WO2008146436A1 (en) * 2007-05-31 2008-12-04 Chemicrea Inc. Stable microbiocidal composition
CN103570642B (en) * 2012-08-01 2015-03-18 中国中化股份有限公司 Isothiazolinone compound and application thereof as bactericide
CN103030733B (en) * 2012-12-06 2014-12-10 青岛大学 Polyacrylate antifouling copolymerization resin with side chain comprising benzisothiazolinone and preparation method thereof
CN103319433A (en) * 2013-07-08 2013-09-25 王建国 Production technology of CMI (cell-mediated immunity) industrial antibacterial agent
CN106472520A (en) * 2016-09-23 2017-03-08 江苏辉丰农化股份有限公司 A kind of composition pesticide
US20210204548A1 (en) * 2017-04-04 2021-07-08 Thor Gmbh Stabilized Biocide Composition
WO2019138814A1 (en) 2018-01-12 2019-07-18 富士フイルム株式会社 Chemical solution, and method for treating substrate
JP7043366B2 (en) * 2018-08-08 2022-03-29 エステー株式会社 Solid volatilization preparation
CN109964947A (en) * 2019-04-12 2019-07-05 嘉兴沃特泰科环保科技有限公司 Non-oxidative antimicrobial
CN110037041A (en) * 2019-04-30 2019-07-23 三河市霍夫曼化学品制造有限公司 A kind of isothiazolinone built-up microemulsion type biocide mildewcide, preparation method and application
CN111087653A (en) * 2019-11-13 2020-05-01 嘉兴学院 Preservative for waterborne polyurethane emulsion and preparation method thereof
CN113549358A (en) * 2021-07-28 2021-10-26 陕西省石油化工研究设计院 Composite preservative for paint and preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0540213A1 (en) * 1991-10-30 1993-05-05 Rohm And Haas Company Bromate as an inhibitor of nitrosamine formation in nitrate stabilized isothiazolones

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870795A (en) * 1973-02-28 1975-03-11 Rohm & Haas Stabilization of solutions of 3-isothiazolones employing certain metal nitrates and nitrites
US4067878A (en) * 1976-03-05 1978-01-10 Rohm And Haas Company Stabilization of solutions of 3-isothiazolones
US4975109A (en) * 1988-05-02 1990-12-04 Lester Technologies Corp. Microbiocidal combinations of materials and their use
US5424324A (en) * 1989-11-17 1995-06-13 Rohm And Haas Company Use of carbonyl stabilizers for 3-isothiazolones
US5145501A (en) * 1991-11-12 1992-09-08 Rohm And Haas Company Bromate stabilizers for 3-isothiazolones
JP3176676B2 (en) * 1991-12-24 2001-06-18 ローム アンド ハース カンパニー Sterilizing composition
US5910503A (en) * 1997-10-28 1999-06-08 Rohm And Haas Company Stable microbicide formulation
KR100315355B1 (en) * 1999-08-26 2001-11-30 류정열 A mold for trunk floor having heat pipes for cooling itself
KR100385714B1 (en) * 1999-12-31 2003-05-27 에스케이케미칼주식회사 A stabilized isothiazolone composition and method of stabilization of isothiazolone
US6403533B2 (en) * 2000-01-27 2002-06-11 Rohm And Haas Company Stabilized microbicide formulation
KR100740054B1 (en) * 2000-10-13 2007-07-16 에스케이케미칼주식회사 Isothiazolone composition
KR100703996B1 (en) * 2001-05-08 2007-04-04 에스케이케미칼주식회사 Isothiazolone composition and stabilizing method, and method for suppressing micro-organism using the same
KR100703997B1 (en) * 2001-05-08 2007-04-04 에스케이케미칼주식회사 Isothiazolone composition and stabilizing method, and method for suppressing micro-organism using the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0540213A1 (en) * 1991-10-30 1993-05-05 Rohm And Haas Company Bromate as an inhibitor of nitrosamine formation in nitrate stabilized isothiazolones

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO03099799A1 *

Also Published As

Publication number Publication date
JP2005527626A (en) 2005-09-15
CN100400521C (en) 2008-07-09
AU2003232654B2 (en) 2007-05-17
AU2003232654A1 (en) 2003-12-12
EP1507771A4 (en) 2006-08-30
CN1671674A (en) 2005-09-21
WO2003099799A1 (en) 2003-12-04

Similar Documents

Publication Publication Date Title
EP0686347A2 (en) Composition containing 3-isothialozolone and stabilizer
EP1507771A1 (en) Isothiazolone composition and method for stabilizing isothiazolone
JP4382175B2 (en) Stable microbicide formulation
EP0315464B1 (en) Stabilized isothiazolone compositions
JP7478445B2 (en) Stable microbicidal composition
KR20010077985A (en) Stabilized microbicide formulation
KR100703996B1 (en) Isothiazolone composition and stabilizing method, and method for suppressing micro-organism using the same
US5668083A (en) Composition containing 3-isothiazolone and stabilizer
EP0606986B1 (en) Iron stabilizers for 3-isothiazolones
US20050165073A1 (en) Isothiazolone composition and method for stabilizing isothiazolone
JP2005082596A (en) Low-salt or salt-free microbicidal composition based on isothiazolone derivative and pyrion disulfide
KR100703995B1 (en) Isothiazolone composition and stabilizing method, and method for suppressing micro-organism using the same
KR100703997B1 (en) Isothiazolone composition and stabilizing method, and method for suppressing micro-organism using the same
KR100975372B1 (en) Isothiazolone composition and method for stabilizing isothiazolone
KR101074036B1 (en) Composition including methyl isothiazolone compound and a method for preapring the same
JP2834219B2 (en) Industrial sterilization / bacteriostatic composition stabilization method
CN110536603A (en) Stabilized biocidal composition
KR100694833B1 (en) Isothiazolone composition, stabilizing method thereof, and method for suppressing micro-organism using the same
KR20020029527A (en) Isothiazolone composition
JP3930593B2 (en) Method for producing 3-isothiazolinone composition having bactericidal or bacteriostatic action
EP0686346B1 (en) Composition containing 3-isothiazolone and stabilizer
JPWO2008146436A1 (en) Stable microbicidal composition
JP3930593B6 (en) Method for producing 3-isothiazolinone composition having bactericidal or bacteriostatic action
AU3442889A (en) A dry microbiocidal composition containing an ethylene bis-dithiocarbamate salt

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041122

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20060801

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 275/06 20060101ALI20060726BHEP

Ipc: C07D 275/03 20060101AFI20031208BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080408